The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Trastuzumab‐associated cardiotoxicity
Open accessAbstract
Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the HER2 protein. Cardiotoxicity has been reported to occur with trastuzumab when administered alone and in combination with antineoplastic agents, particularly anthracyclines. The risk of cardiotoxicity with trastuzumab has been reported to be 4% with monotherapy and 27% when administered in combination with an anthracycline and cyclophosphamide, but to the author's knowledge severe outcomes, such as death or permanent disability, are uncommon. The majority of reported cardiac effects are mild to moderate, nonspecific, and medically manageable. Signs and symptoms are similar to those observed in patients who develop anthracycline‐induced cardiomyopathy and include tachycardia, palpitations, and exertional dyspnea, which may progress to congestive heart failure. The pathogenesis and histologic changes responsible for trastuzumab‐associated cardiotoxicity currently are under investigation. Unlike anthracycline‐induced toxicity, trastuzumab‐associated toxicity usually responds to standard treatment or the discontinuation of trastuzumab, and there is no evidence that the toxicity is dose related. Current methods for the early detection of cardiotoxicity in trastuzumab‐treated patients are similar to those used in anthracycline‐treated patients. Cardiac function is established at baseline and monitored regularly during treatment by physical examination and measurement of left ventricular ejection fraction. The majority of patients improve with proper treatment, and some are able to continue to receive trastuzumab. Cancer 2002;95:1592–600. © 2002 American Cancer Society. DOI 10.1002/cncr.10854
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Self-citationRequirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Stress Pathways and Heart Failure
Chien, K. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80043-4 · Cited by 446
Burstein, H. J., Kuter, I., Campos, S. M., Gelman, R. S., Tribou, L., Parker, L. M., Manola, J., Younger, J., Matulonis, U., Bunnell, C. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2722 · Cited by 366
Heart Failure Society Of America (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)91340-4 · Cited by 336
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
Toikkanen, S., Helin, H., Isola, J., & Joensuu, H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1044 · Cited by 313
Baselga, J. M., Tripathy, D., Mendelsohn, J., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1999) · PubMed · Cited by 300
HEART FAILURE SOCIETY OF AMERICA (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.6.495.35164 · Cited by 250
Lemke, G. (1996) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1996.0019 · Cited by 223
Guidelines for the Evaluation and Management of Heart Failure
(1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00469-6 · Cited by 223
Structure-Function relationships for the EGF/TGF-α family of mitogens
Groenen, L. C., Nice, E. C., & Burgess, A. W. (1994) · Growth Factors · doi:10.3109/08977199409010997 · Cited by 216
Tjeerdsma, G., Meinardi, M. T., van der Graaf, W. T. A., van den Berg, M. P., Mulder, N. H., Crijns, H. J. G. M., de Vries, E. G. E., & van Veldhuisen, D. J. (1999) · Heart · doi:10.1136/hrt.81.4.419 · Cited by 115
Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials
Sparano, J. A. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90189-7 · Cited by 93
Valero, V., Buzdar, A. U., Theriault, R. L., Azarnia, N., Fonseca, G. A., Willey, J. S., Ewer, M. S., Walters, R. S., Mackay, B., Podoloff, D. A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1425 · Cited by 85
Cited by
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury
Bersell, K., Arab, S., Haring, B., & Kühn, B. (2009) · Cell · doi:10.1016/j.cell.2009.04.060 · Cited by 1,032
Metadata
- Authors
- Keefe, D. L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-09-17
- Volume
- 95
- Issue
- 7
- Pages
- 1592-1600
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2029059005
- Cited by
- 358
- References
- 25
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.